LC-MS/MS determination of avanafil and its metabolites in rat plasma and brain: pharmacokinetic study after oral administration and transdermal film application

Avanafil (AVA) has been FDA approved in 2012 as a phosphodiesterase-type five inhibitor drug (PDE-5), for the treatment of erectile dysfunction (ED). It was necessary to study the pharmacokinetics and bioavailability parameters of AVA since it exhibits side effects, a long time from drug administrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kammoun, Ahmed K., Khedr, Alaa, Ahmed, Osama A. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2020
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050051/
https://www.ncbi.nlm.nih.gov/pubmed/35497213
http://dx.doi.org/10.1039/d0ra00569j

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050051/
https://www.ncbi.nlm.nih.gov/pubmed/35497213
http://dx.doi.org/10.1039/d0ra00569j

Ejemplares similares